NICE issued the draft guidance recommending rimegepant for preventive use on the NHS in England to prevent migraines in adults who have at least four and fewer than 15 migraine attacks a month
The clinical trial evidence showed that rimegepant works better than other treatments for reducing the number of episodic migraines in patients
NICE is expected to publish final guidance on rimegepant for preventing episodic migraines in the next month. Additionally, NICE recommended erenumab, fremanezumab or galcanezumab are antibody proteins engineered to target and neutralize other proteins or their receptors
Ref: Nice | Image: Pfizer
Related News:- Pfizer and Biohaven’s Vydura (Rimegepant) Receive EC’s Marketing Authorization for the Treatment of Migraine and Prophylaxis of Episodic Migraine
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
